Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease

Objective: To evaluate the frequency of glucocerebrosidase (GBA) mutations in cases and controls enrolled in the Genetic Epidemiology of Parkinson’s Disease (GEPD) study. Methods: We sequenced all exons of the GBA gene in 278 Parkinson disease (PD) cases and 179 controls enrolled in GEPD, with a wide range of age at onset (AAO), and that included a subset of 178 Jewish cases and 85 Jewish controls. Cases and controls were recruited without knowledge of family history of PD, and cases were oversampled in the AAO < 50 years category. Results: 13.7% of PD cases (38/278) carried GBA mutations, compared with 4.5% of controls (8/179) (odds ratio [OR] 3.4, 95% CI 1.5 to 7.4). The frequency of GBA mutations was 22.2% in 90 cases with AAO ≤ 50 years, compared with 9.7% in 185 cases with AAO > 50 years (OR 2.7, 95% CI 1.3 to 5.3). Adjusting for age at the time of evaluation, sex, family history of PD, and Jewish ancestry, GBA carriers had a 1.7-year-earlier AAO of PD (95% CI 0.5 to 3.3, p < 0.04) than noncarriers. The average AAO of PD was 2.5 years earlier in carriers with an AAO ≤ 50 years compared with noncarriers (95% CI 0.6 to 4.5, p < 0.01) and this was not seen in the AAO > 50 years group. The frequency of GBA mutations was higher in a subset of 178 cases that reported four Jewish grandparents (16.9%) than in cases who did not report Jewish ancestry (8.0%) (p < 0.01). Nine different GBA mutations were identified in PD cases, including 84insGG, E326K, T369M, N370S, D409H, R496H, L444P, RecNciI, and a novel mutation, P175P. Conclusions: This study suggests that the Glucocerebrosidase gene may be a susceptibility gene for Parkinson disease and that Glucocerebrosidase mutations may modify age at onset. GLOSSARY: AAO = age at onset; cDNA = complementary DNA; GBA = glucocerebrosidase; GD = Gaucher disease; GEPD = Genetic Epidemiology of Parkinson’s Disease; MMSE = Mini-Mental State Examination; NA = not applicable; DLB = dementia with Lewy bodies; OR = odds ratio; PD = Parkinson disease; SNP = single nucleotide polymorphism; UPDRS = Unified Parkinson’s Disease Rating Scale.

[1]  K. Marder,et al.  Distribution, type, and origin of Parkin mutations: Review and case studies , 2004, Movement disorders : official journal of the Movement Disorder Society.

[2]  A. Singleton,et al.  Analysis of an early‐onset Parkinson's disease cohort for DJ‐1 mutations , 2004, Movement disorders : official journal of the Movement Disorder Society.

[3]  N. Quinn,et al.  A heterozygous effect for PINK1 mutations in Parkinson's disease? , 2006, Annals of neurology.

[4]  E. Sidransky,et al.  Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease , 2000, Human mutation.

[5]  Alexandra Durr,et al.  How much phenotypic variation can be attributed to parkin genotype? , 2003, Annals of neurology.

[6]  G. Schroth,et al.  Early diagnosis of herpes simplex encephalitis by MRI , 1987, Neurology.

[7]  M. Farrer,et al.  PINK1 mutation heterozygosity and the risk of Parkinson’s disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[8]  E D Louis,et al.  Accuracy of family history data on Parkinson’s disease , 2003, Neurology.

[9]  R. Schiffmann,et al.  Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? , 2003, Molecular genetics and metabolism.

[10]  L. Seeberger,et al.  Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease , 2003, Neurology.

[11]  B. Cormand,et al.  Molecular analysis and clinical findings in the Spanish Gaucher disease population: Putative haplotype of the N370S ancestral chromosome , 1998, Human mutation.

[12]  Karl Herholz,et al.  The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans , 2002, Neuroscience Letters.

[13]  Yaakov Stern,et al.  Modified Mini-Mental State Examination: Validity and Reliability , 1987 .

[14]  J. Aharon-Peretz,et al.  Gaucher disease associated with parkinsonism: Four further case reports , 2003, American journal of medical genetics. Part A.

[15]  R. Mcpherson,et al.  Gaucher disease: gene frequencies in the Ashkenazi Jewish population. , 1993, American journal of human genetics.

[16]  M. Ranke,et al.  Early-Onset Idiopathic Growth Hormone Deficiency within KIGS , 2003, Hormone Research in Paediatrics.

[17]  K. Marder,et al.  Evaluation of 50 probands with early-onset Parkinson’s disease for Parkin mutations , 2002, Neurology.

[18]  Jean-François Deleuze,et al.  Complex relationship between Parkin mutations and Parkinson disease. , 2002, American journal of medical genetics.

[19]  Nir Giladi,et al.  Occurrence of Parkinson's syndrome in type I Gaucher disease. , 1996, QJM : monthly journal of the Association of Physicians.

[20]  M. Farrer,et al.  Clinical findings in a large family with a parkin ex3delta40 mutation. , 2004, Archives of neurology.

[21]  J. Aharon-Peretz,et al.  Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. , 2004, The New England journal of medicine.

[22]  M. Farrer,et al.  Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population , 2006, Neurology.

[23]  M. Farrer,et al.  Parkin mutations and early-onset parkinsonism in a Taiwanese cohort. , 2005, Archives of neurology.

[24]  M. Farrer,et al.  Clinical Findings in a Large Family With a Parkin Ex3Δ40 Mutation , 2004 .

[25]  J. Trojanowski,et al.  Glucocerebrosidase mutations are an important risk factor for Lewy body disorders , 2006, Neurology.

[26]  Thomas D. Bird,et al.  parkin mutation analysis in clinic patients with early‐onset Parkinson's disease , 2004 .

[27]  P. S. St George-Hyslop,et al.  Analysis of the glucocerebrosidase gene in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[28]  Janel O. Johnson,et al.  Parkin disease in a Brazilian kindred: Manifesting heterozygotes and clinical follow‐up over 10 years , 2005, Movement disorders : official journal of the Movement Disorder Society.

[29]  D. Krasnewich,et al.  Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. , 2001, Molecular genetics and metabolism.

[30]  K. Marder,et al.  Case-control study of the parkin gene in early-onset Parkinson disease. , 2006, Archives of neurology.

[31]  Karen Marder,et al.  Familial aggregation of early‐ and late‐onset Parkinson's disease , 2003, Annals of neurology.

[32]  T. Gillis,et al.  Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. , 2006, Archives of neurology.

[33]  J. Noth,et al.  DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease , 2004, Neurology.

[34]  A. Singleton,et al.  Glucocerebrosidase mutations are also found in subjects with early‐onset parkinsonism from Venezuela , 2006, Movement disorders : official journal of the Movement Disorder Society.

[35]  K. Marder,et al.  Pilot association study of the β‐glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity , 2005, Movement disorders : official journal of the Movement Disorder Society.

[36]  E. Sidransky.  Gaucher disease: complexity in a "simple" disorder. , 2004, Molecular genetics and metabolism.

[37]  Diane C. Tsai.  Recent Developments in Parkinson's Disease , 1986, The Yale Journal of Biology and Medicine.

[38]  R. Marconi,et al.  Novel parkin mutations detected in patients with early‐onset Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[39]  Y. Agid,et al.  A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. , 1999, Human molecular genetics.

[40]  H. Ostrer.  A genetic profile of contemporary Jewish populations , 2001, Nature Reviews Genetics.

[41]  O. Amaral,et al.  Adult-onset neuronopathic form of Gaucher's disease: a case report. , 2003, Parkinsonism & related disorders.

[42]  A. Skotnicki,et al.  Parkinson's syndrome preceding clinical manifestation of Gaucher's disease , 1999, American journal of hematology.

[43]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[44]  M. Farrer,et al.  Parkin variants in North American Parkinson's disease: Cases and controls , 2003, Movement disorders : official journal of the Movement Disorder Society.

[45]  E. Sidransky,et al.  Glucocerebrosidase mutations in subjects with parkinsonism. , 2004, Molecular genetics and metabolism.

[46]  W D Heiss,et al.  Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial Parkinsonism associated with mutations in the Parkin gene , 2001, Annals of neurology.

[47]  P. Pramstaller,et al.  Heterozygous PINK1 mutations: A susceptibility factor for Parkinson disease? , 2006, Movement disorders : official journal of the Movement Disorder Society.

[48]  N. Hattori,et al.  Dopaminergic neuronal dysfunction associated with parkinsonism in both a Gaucher disease patient and a carrier , 2007, Journal of the Neurological Sciences.

[49]  J. Haines,et al.  Parkin mutations and susceptibility alleles in late‐onset Parkinson's disease , 2003, Annals of neurology.